Kyongbo Pharmaceutical Co., Ltd
Kyongbo Pharmaceutical Co., Ltd (KRX: 214390) is trading at ₩5,500.00, about ₹397 at today's KRW/INR rate, as of 8 Oct 2026, 2:30 AM ET. Kyongbo Pharmaceutical is not currently available to trade on Paasa; this page shows its price, statistics and the Indian tax treatment for information.
Quote
Today's low
₩5,430.00
Today's high
₩5,550.00
52 week low
₩4,700.00
52 week high
₩9,300.00
214390 opened at ₩5,500.00, closed previously at ₩5,500.00, and has traded between ₩4,700.00 and ₩9,300.00 over the past 52 weeks.
About
Established in 1987 and based in Asan, South Korea, Kyongbo Pharmaceutical Co., Ltd is a key player in the South Korean pharmaceutical market, primarily focusing on the production and distribution of active pharmaceutical ingredients (APIs). Its API offerings span general, cephalosporin, and anti-cancer categories. Beyond APIs, the company also supplies a range of finished pharmaceutical products, including prescription medications for anesthetic, cardiovascular, and digestive uses, as well as antibiotics, alongside its over-the-counter (OTC) drug portfolio. Kyongbo Pharmaceutical extends its reach internationally, exporting its goods to 30 countries worldwide. The company officially adopted its current name, Kyongbo Pharmaceutical Co., Ltd, in March 2002, having previously been known as Kyongbo Chemical Co. Ltd.
Key statistics
Avg. volume
51.21K
Market cap
₩131.49B
P/E Ratio
26.44
Price-to-sales ratio
0.47
Enterprise value
₩257.19B
Free cash flow yield
-24.74%
Debt-to-equity ratio
1.07
Return on equity
0.13%
ROIC
0.52%
Beta
0.30
Dividend yield
0.91%
Last dividend
₩50.00
Financial overview
Revenue
₩264.10B
Earnings per share
₩7.63
Free cash flow
-₩34.08B
Net profit margin
1.78%
Gross margin
37.24%
EBITDA
₩16.72B
Revenue growth
10.71%
Similar securities
This is not an investment recommendation
Kyongbo Pharmaceutical for Indian investors
Kyongbo Pharmaceutical is listed on the Korea Exchange. It is not currently available to trade on Paasa; the figures on this page are for information, and the tax notes below apply to Indian residents who hold it.
Taxes on Kyongbo Pharmaceutical for Indian residents
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm KST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- Slab rateDividends are taxed at your slab rate in India. Kyongbo Pharmaceutical’s current yield is 0.91%.Dividend tax explained
FAQs
Can I buy Kyongbo Pharmaceutical on Paasa?
Kyongbo Pharmaceutical (214390) has been listed on the Korea Exchange since 2015, in the Drug Manufacturers - Specialty & Generic industry. Kyongbo Pharmaceutical is not currently available to trade on Paasa; the figures on this page are for information. Indian residents who hold it through another broker still declare it under the rules below.
How much does one Kyongbo Pharmaceutical share cost in rupees?
One Kyongbo Pharmaceutical share is ₩5,500.00 — about ₹397 at a KRW/INR rate of 0.0722 on 8 Oct 2026. Both the Kyongbo Pharmaceutical price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for investing abroad from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability.
How are gains on Kyongbo Pharmaceutical shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the KRW/INR rate on the purchase and the sale date, so the rupee move counts alongside the Kyongbo Pharmaceutical price.
Does Kyongbo Pharmaceutical pay a dividend, and how is it taxed in India?
Yes. Kyongbo Pharmaceutical pays a dividend and the current yield is 0.91%; the last declared dividend was ₩50.00 per share, about ₹3.61. Dividends are taxed at your slab rate in India.
When does KRX trade, in Indian time?
The Korea Exchange trades 5:30 am – 12:00 pm IST in Indian time.
Do I have to declare Kyongbo Pharmaceutical shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. The holding is reported with its cost and its closing value.
Does the rupee rate affect what I make on Kyongbo Pharmaceutical?
Yes. Kyongbo Pharmaceutical is priced in KRW, so your rupee outcome combines the KRW move with the KRW/INR move between the day you remit and the day you convert back.